Merck's HPV Vaccine Gardasil Effective For Five Years, Analysis Of Phase II Trial Says

Main Category: Immune System / Vaccines
Also Included In: Cancer / Oncology;  Cervical Cancer / HPV Vaccine
Article Date: 28 Apr 2006 - 1:00 PDT

email to a friend   printer friendly   opinions  

Sanofi Pasteur -- the Merck- and Sanofi Aventis-owned vaccine producer -- on Wednesday announced that an analysis of a Phase II clinical trial of the company's experimental human papillomavirus vaccine Gardasil shows that it is effective in preventing cervical neoplasia and external lesions for five years, AFX/Euro2day reports (AFX/Euro2day, 4/26). Merck in October 2005 announced that Gardasil in clinical trials was 100% effective in preventing infection with HPV strains 16 and 18, which together cause about 70% of cervical cancer cases. The company in February announced that FDA had granted priority review for Gardasil and has said it expects FDA to act on its application by June 8 (Kaiser Daily Women's Health Policy Report, 4/6).

"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

• Additional
• References
• Citations